Univariate analysis of examined parameters for overall survival (OS)
| Total (n) | DOD (n) | Median OS (CI) | p Value | |
|---|---|---|---|---|
| CI, confidence interval; DOD, died of disease; ER, oestrogen receptor; p34cdc2bn, p34cdc2 expression in benign breast tissue; p34cdc2TC, p34cdc2 expression in tumour cytoplasm; p34cdc2TN, p34cdc2 expression in tumour nuclei; PR, progesterone receptor. | ||||
| Age (years) | ||||
| <50 | 40 | 3 | 73 (65–81) | 0.9560 |
| ⩾50 | 54 | 5 | 68 (60–76) | |
| Menopausal | ||||
| Pre | 35 | 2 | 73 (63–83) | 0.1785 |
| Post | 57 | 4 | 70 (53–87) | |
| T size | ||||
| T1 | 44 | 2 | 68 (62–74) | 0.5203 |
| T2 | 50 | 6 | 75 (57–93) | |
| Grade | ||||
| 1 | 21 | 1 | 67 (36–98) | 0.9815 |
| 2 | 38 | 3 | 82 (68–96) | 0.9164 |
| 3 | 35 | 4 | 69 (64–74) | 0.6925 |
| p34cdc2TN | ||||
| <10% | 14 | 1 | 62 (53–71) | 0.1065 |
| ⩾10% | 80 | 7 | 73 (59–87) | |
| p34cdc2TC | ||||
| <10% | 29 | 3 | 67 (62–72) | 0.0715 |
| ⩾10% | 62 | 5 | 75 (58–92) | |
| p34cdc2bn | ||||
| <10% | 62 | 5 | 69 (63–75) | 0.0046 |
| ⩾10% | 12 | 1 | 102 (26–178) | |
| p53 | ||||
| <10% | 69 | 8 | 72 (60–84) | 0.7237 |
| ⩾10% | 21 | 0 | 69 (63–75) | |
| p21WAF1 | ||||
| <6% | 48 | 5 | 69 (63–75) | 0.5611 |
| ⩾6% | 46 | 3 | 77 (59–95) | |
| ER | ||||
| Negative | 37 | 4 | 69 (62–76) | 0.9610 |
| Positive | 54 | 4 | 72 (62–82) | |
| PR | ||||
| Negative | 46 | 5 | 68 (62–74) | 0.5110 |
| Positive | 47 | 3 | 77 (64–90) | |